Severe obesity disqualifies most candidates from a heart transplant list. The cutoff varies by program, but body mass index above 35 is the line most centers draw, and the line the paper out of Sydney this week reports walking nine end-stage heart failure patients across.
Cardiologists at St. Vincent's Hospital and the Victor Chang Cardiac Research Institute prescribed semaglutide to nine outpatients who were carrying severe obesity into a transplant evaluation, watched their weight come off, and put all nine onto the active waiting list. Seven of the nine were transplanted during follow-up. The findings appeared online April 14 in JHLT Open ↗.
The cohort is small and the study is retrospective. The framing is what makes the piece. This is not another weight-loss outcome paper. It is a paper about a clinical decision point at which semaglutide does or does not change who gets considered for a transplant at all.
The setup
The nine outpatients carried a median body mass index of 35.9 kg per square meter before treatment, with an interquartile range of 1.3 around that median. Seven of the nine were above 35, the threshold at which the Sydney program would not typically list a candidate. The team prescribed once-weekly semaglutide and tracked metabolic and listing outcomes for a median of 4 months, with the interquartile range widening to 9 months (some patients stayed on the drug substantially longer than others).
The drop was modest by current obesity-drug standards but mattered for the cutoff. Median body mass index fell from 35.9 to 32.2, an interquartile range of 4.1 around the post-treatment value. Median weight loss was 5.0 kg, with an interquartile range of 6.3 kg. Five kilograms over four months is in the range you would expect from semaglutide in a heart-failure outpatient with severe obesity. The drug is being used here to clear a threshold, not to chase the high-percent weight-loss numbers that anchored STEP and SELECT coverage.
What changed
All nine patients were transplant-listed. Seven (78 percent) underwent transplantation during follow-up. No significant adverse effects were reported in the cohort.
That is the entire numerical story. There is no comparator arm, no randomization, no blinding. The authors frame the findings as preliminary, and they are. The listing-and-transplant outcome is a binary that does not arise in most GLP-1 trials. The typical cardiovascular endpoint is mortality, hospital readmission, or change in ejection fraction. Whether a patient gets an organ does not show up in SELECT or FLOW or STEP-HFpEF.
Why this fits a specific clinical hole
End-stage heart failure with severe obesity is a high-risk subgroup that gets weight-loss surgery hesitantly. Bariatric surgery in a candidate already running on a left-ventricular assist device, or already in NYHA class IV, is its own large-scale risk, and most centers will not perform it without considerable preparation. A weekly injection that drops body mass index by 4 points over a few months avoids that calculus entirely and opens a path to listing that the surgical option keeps closed.
The platform card for semaglutide ↗ already collects the cardiovascular outcomes data from SELECT (the 20 percent reduction in major adverse cardiovascular events that anchored the European Medicines Agency CHMP positive opinion for the Wegovy pill ↗ last week), plus this week's findings on intracranial aneurysm rupture ↗ and lung cancer metastasis ↗. The transplant-bridge case is the smallest and shabbiest signal in that pile, with a sample size of nine. It is also the one with the cleanest binary endpoint: either the patient gets listed and gets an organ, or they do not.
What the next study needs
A larger multi-center series with a comparator (lifestyle-only, or a different GLP-1 receptor agonist) and explicit time-to-listing and time-to-transplant analyses. Whether semaglutide accelerates the listing decision or merely enables it is unanswered here. Whether 78 percent of a larger cohort would still be transplanted, or whether the high success rate reflects how carefully the Sydney team selected patients, is also unanswered. The piece does not pretend to resolve either.
There is also a question the JHLT Open paper does not raise but a transplant cardiologist will. GLP-1 receptor agonists carry the dysesthesia and gastrointestinal signals that recent VigiBase mining attached to the class, and the post-transplant immunosuppression cocktail interacts with appetite, glycemia, and fluid balance in ways that have not been studied alongside a chronic weekly incretin agonist. The Sydney team reported no significant adverse effects pre-transplant, but the post-transplant phase is where the safety question lives.
Nine patients is a case series. Nine patients getting listed for transplants because of an obesity drug is a clinical pathway.